

# Daniel E Singer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/548248/publications.pdf>

Version: 2024-02-01

125  
papers

24,751  
citations

61857

43  
h-index

18075

120  
g-index

131  
all docs

131  
docs citations

131  
times ranked

18329  
citing authors

#	ARTICLE	IF	CITATIONS
1	Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 883-891.	13.9	8,006
2	Prevalence of Diagnosed Atrial Fibrillation in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2001, 285, 2370.	3.8	5,547
3	Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2003, 349, 1019-1026.	13.9	1,136
4	Estimates of Current and Future Incidence and Prevalence of Atrial Fibrillation in the U.S. Adult Population. <i>American Journal of Cardiology</i> , 2013, 112, 1142-1147.	0.7	1,032
5	Antithrombotic Therapy for Atrial Fibrillation. <i>Chest</i> , 2012, 141, e531S-e575S.	0.4	891
6	The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2009, 2, 474-480.	2.1	747
7	Antithrombotic Therapy in Atrial Fibrillation. <i>Chest</i> , 2008, 133, 546S-592S.	0.4	706
8	The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation. <i>Annals of Internal Medicine</i> , 2009, 151, 297.	2.0	585
9	The Effect of Warfarin and Intensity of Anticoagulation on Outcome of Intracerebral Hemorrhage. <i>Archives of Internal Medicine</i> , 2004, 164, 880.	4.3	544
10	Antithrombotic Therapy in Atrial Fibrillation. <i>Chest</i> , 2004, 126, 429S-456S.	0.4	519
11	A New Risk Scheme to Predict Ischemic Stroke and Other Thromboembolism in Atrial Fibrillation: The ATRIA Study Stroke Risk Score. <i>Journal of the American Heart Association</i> , 2013, 2, e000250.	1.6	315
12	Moving the Tipping Point. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 14-21.	0.9	234
13	Patients'™ time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. <i>American Heart Journal</i> , 2015, 170, 141-148.e1.	1.2	211
14	Intracranial Hemorrhage Among Patients With Atrial Fibrillation Anticoagulated With Warfarin or Rivaroxaban. <i>Stroke</i> , 2014, 45, 1304-1312.	1.0	187
15	Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 61, 651-658.	1.2	181
16	Atrial Fibrillation Burden and Short-Term Risk of Stroke. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 1040-1047.	2.1	168
17	Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. <i>European Heart Journal</i> , 2014, 35, 3377-3385.	1.0	154
18	Perioperative/Postoperative Atrial Fibrillation and Risk of Subsequent Stroke and/or Mortality. <i>Stroke</i> , 2019, 50, 1364-1371.	1.0	147

#	ARTICLE	IF	CITATIONS
19	The relation between expectations and outcomes in surgery for sciatica. <i>Journal of General Internal Medicine</i> , 1999, 14, 740-744.	1.3	127
20	Cause of Death and Predictors of All-cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. <i>Journal of the American Heart Association</i> , 2016, 5, e002197.	1.6	127
21	Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1325-1335.	1.2	124
22	Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). <i>Lancet</i> , The, 2015, 385, 2363-2370.	6.3	123
23	Sustained Care Intervention and Postdischarge Smoking Cessation Among Hospitalized Adults. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 719.	3.8	114
24	Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2018, 3, 1174.	3.0	111
25	Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). <i>American Heart Journal</i> , 2014, 168, 487-494.	1.2	107
26	Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	106
27	Wide Variation in Reported Rates of Stroke Across Cohorts of Patients With Atrial Fibrillation. <i>Circulation</i> , 2017, 135, 208-219.	1.6	103
28	Should Patient Characteristics Influence Target Anticoagulation Intensity for Stroke Prevention in Nonvalvular Atrial Fibrillation?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 297-304.	0.9	96
29	Comparison of the ATRIA, CHADS <sub>2</sub> , and CHA <sub>2</sub> DS <sub>2</sub> -VASc stroke risk scores in predicting ischaemic stroke in a large Swedish cohort of patients with atrial fibrillation. <i>European Heart Journal</i> , 2016, 37, 3203-3210.	1.0	93
30	Thirty-Day Mortality After Ischemic Stroke and Intracranial Hemorrhage in Patients With Atrial Fibrillation On and Off Anticoagulants. <i>Stroke</i> , 2012, 43, 1795-1799.	1.0	78
31	Association of of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes. <i>JAMA Cardiology</i> , 2018, 3, 54.	3.0	77
32	Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 23	0.7	74
33	Effect of Diabetes and Glycemic Control on Ischemic Stroke Risk in AF Patients. <i>Journal of the American College of Cardiology</i> , 2016, 67, 239-247.	1.2	71
34	Novel oral anticoagulants and reversal agents: Considerations for clinical development. <i>American Heart Journal</i> , 2015, 169, 751-757.	1.2	69
35	Effect of Selective Serotonin Reuptake Inhibitors on Bleeding Risk in Patients With Atrial Fibrillation Taking Warfarin. <i>American Journal of Cardiology</i> , 2014, 114, 583-586.	0.7	68
36	Clinical presentation, processes and outcomes of care for patients with pneumococcal pneumonia. <i>Journal of General Internal Medicine</i> , 2000, 15, 638-646.	1.3	67

#	ARTICLE	IF	CITATIONS
37	A Controlled Trial of Population Management: Diabetes Mellitus: Putting Evidence into Practice (DM-PEP). <i>Diabetes Care</i> , 2004, 27, 2299-2305.	4.3	62
38	Rationale and design of a large population study to validate software for the assessment of atrial fibrillation from data acquired by a consumer tracker or smartwatch: The Fitbit heart study. <i>American Heart Journal</i> , 2021, 238, 16-26.	1.2	61
39	Defining Clinically Important Difference in the Atrial Fibrillation Effect on Quality-of-Life Score. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005358.	0.9	59
40	Disparities in Cancer Incidence, Stage, and Mortality at Boston Health Care for the Homeless Program. <i>American Journal of Preventive Medicine</i> , 2015, 49, 694-702.	1.6	56
41	Health Literacy and Awareness of Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	52
42	Use of Oral Anticoagulant Therapy in Older Adults with Atrial Fibrillation After Acute Ischemic Stroke. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 241-248.	1.3	48
43	Temporal Association Between Episodes of Atrial Fibrillation and Risk of Ischemic Stroke. <i>JAMA Cardiology</i> , 2021, 6, 1364.	3.0	47
44	A Post-Discharge Smoking-Cessation Intervention for Hospital Patients. <i>American Journal of Preventive Medicine</i> , 2016, 51, 597-608.	1.6	44
45	First Diagnosis of Atrial Fibrillation at the Time of Stroke. <i>Cerebrovascular Diseases</i> , 2017, 43, 192-199.	0.8	43
46	Screening for Atrial Fibrillation in Older Adults at Primary Care Visits: VITAL-AF Randomized Controlled Trial. <i>Circulation</i> , 2022, 145, 946-954.	1.6	43
47	Cigarette Smoking and Risk Perceptions During the COVID-19 Pandemic Reported by Recently Hospitalized Participants in a Smoking Cessation Trial. <i>Journal of General Internal Medicine</i> , 2021, 36, 3786-3793.	1.3	42
48	Research Priorities in Atrial Fibrillation Screening. <i>Circulation</i> , 2021, 143, 372-388.	1.6	42
49	Identifying Patients With High Data Completeness to Improve Validity of Comparative Effectiveness Research in Electronic Health Records Data. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 899-905.	2.3	40
50	Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice. <i>Annals of Internal Medicine</i> , 2017, 167, 845.	2.0	37
51	Initial Precipitants and Recurrence of Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e007716.	2.1	37
52	Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban. <i>Heart</i> , 2016, 102, 1036-1043.	1.2	36
53	Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial). <i>American Journal of Cardiology</i> , 2017, 120, 588-594.	0.7	36
54	Risk factors for medication non-adherence among atrial fibrillation patients. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 38.	0.7	36

#	ARTICLE	IF	CITATIONS
55	Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF. <i>Europace</i> , 2016, 18, 1135-1142.	0.7	31
56	Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin. <i>Circulation</i> , 2017, 135, 1001-1003.	1.6	30
57	Changes in Use of Anticoagulation in Patients With Atrial Fibrillation Within a Primary Care Network Associated With the Introduction of Direct Oral Anticoagulants. <i>American Journal of Cardiology</i> , 2017, 120, 786-791.	0.7	30
58	Anxiety, Depression, and Adverse Clinical Outcomes in Patients With Atrial Fibrillation Starting Warfarin: Cardiovascular Research Network WAVE Study. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	29
59	Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e007612.	2.1	27
60	Prediction Score for Anticoagulation Control Quality Among Older Adults. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	26
61	Application of outcomes research in occupational low back pain: The Maine Lumbar Spine Study. , 1996, 29, 584-589.		24
62	Electronic physician notifications to improve guideline-based anticoagulation in atrial fibrillation: a randomized controlled trial. <i>Journal of General Internal Medicine</i> , 2018, 33, 2070-2077.	1.3	24
63	Association of Intracranial Hemorrhage Risk With Non-Vitamin K Antagonist Oral Anticoagulant Use vs Aspirin Use. <i>JAMA Neurology</i> , 2018, 75, 1511.	4.5	24
64	Design and rationale of a pragmatic trial integrating routine screening for atrial fibrillation at primary care visits: The VITAL-AF trial. <i>American Heart Journal</i> , 2019, 215, 147-156.	1.2	24
65	Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation. <i>Circulation</i> , 2018, 138, 889-897.	1.6	23
66	Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation. <i>Heart</i> , 2018, 104, 1850-1858.	1.2	23
67	Ischemic and Thrombotic Events Associated with Concomitant Xa-inhibiting Direct Oral Anticoagulants and Antiepileptic Drugs: Analysis of the FDA Adverse Event Reporting System (FAERS). <i>CNS Drugs</i> , 2019, 33, 1223-1228.	2.7	22
68	Disparities in Quality of Primary Care by Resident and Staff Physicians: Is There a Conflict Between Training and Equity?. <i>Journal of General Internal Medicine</i> , 2019, 34, 1184-1191.	1.3	22
69	Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillation. <i>American Heart Journal</i> , 2020, 223, 65-71.	1.2	22
70	Automated Electronic Phenotyping of Cardioembolic Stroke. <i>Stroke</i> , 2021, 52, 181-189.	1.0	22
71	Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1694-1702.	1.1	21
72	Interactive Voice Response Calls to Promote Smoking Cessation after Hospital Discharge: Pooled Analysis of Two Randomized Clinical Trials. <i>Journal of General Internal Medicine</i> , 2017, 32, 1005-1013.	1.3	20

#	ARTICLE	IF	CITATIONS
73	Risk of Ischemic Stroke and Major Bleeding in Patients with Atrial Fibrillation and Cancer. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 104560.	0.7	20
74	Stability of High-Quality Warfarin Anticoagulation in a Community-Based Atrial Fibrillation Cohort: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	19
75	Comparative effectiveness of post-discharge strategies for hospitalized smokers: study protocol for the Helping HAND 2 randomized controlled trial. <i>BMC Public Health</i> , 2015, 15, 109.	1.2	18
76	NOACs for treatment of venous thromboembolism in clinical practice. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1317-1325.	1.8	18
77	Shared decision-making in atrial fibrillation: patient-reported involvement in treatment decisions. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2020, 6, 263-272.	1.8	16
78	Comparison of Frequency and Outcome of Major Gastrointestinal Hemorrhage in Patients With Atrial Fibrillation on Versus Not Receiving Warfarin Therapy (from the ATRIA and ATRIA-CVRN Cohorts). <i>American Journal of Cardiology</i> , 2015, 115, 40-46.	0.7	15
79	Profile of Patients with Isolated Distal Deep Vein Thrombosis versus Proximal Deep Vein Thrombosis or Pulmonary Embolism: RE-COVERY DVT/PE Study. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 446-458.	1.5	15
80	RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate. <i>Thrombosis and Haemostasis</i> , 2017, 117, 415-421.	1.8	14
81	Influence of Competing Risks on Estimating the Expected Benefit of Warfarin in Individuals with Atrial Fibrillation Not Currently Taking Anticoagulants: The Anticoagulation and Risk Factors in Atrial Fibrillation Study. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 35-41.	1.3	13
82	Trends in Consumer Wearable Devices With Cardiac Sensors in a Primary Care Cohort. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2022, 15, .	0.9	13
83	Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2015, 4, e001349.	1.6	12
84	Cost-Effectiveness of Extended and One-Time Screening Versus No Screening for Non-Valvular Atrial Fibrillation in the USA. <i>Applied Health Economics and Health Policy</i> , 2020, 18, 533-545.	1.0	11
85	Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF. <i>International Journal of Cardiology</i> , 2018, 257, 78-83.	0.8	10
86	Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. <i>JAMA Cardiology</i> , 2019, 4, 756.	3.0	10
87	Comparative effectiveness of post-discharge strategies for hospitalized smokers: Study protocol for the Helping HAND 4 randomized controlled trial. <i>Trials</i> , 2020, 21, 336.	0.7	10
88	Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PE Study. <i>American Journal of Medicine</i> , 2020, 133, 936-945.	0.6	10
89	Smoking Cessation After Hospital Discharge: Factors Associated With Abstinence. <i>Journal of Hospital Medicine</i> , 2018, 13, 774-778.	0.7	10
90	Comparative Effectiveness of Postdischarge Smoking Cessation Interventions for Hospital Patients. <i>JAMA Internal Medicine</i> , 2022, 182, 814.	2.6	10

#	ARTICLE	IF	CITATIONS
91	How Well Do Stroke Risk Scores Predict Hemorrhage in Patients With Atrial Fibrillation?. American Journal of Cardiology, 2016, 118, 697-699.	0.7	9
92	Factors influencing left atrial volume in a population with preserved ejection fraction: Left ventricular diastolic dysfunction or clinical factors?. Journal of Cardiology, 2016, 68, 275-281.	0.8	9
93	Improvements in health-related quality of life among smokers who quit after hospitalization. Preventive Medicine, 2018, 110, 38-46.	1.6	9
94	Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	8
95	Ischemic Stroke in Nonvalvular Atrial Fibrillation at Warfarin Initiation. Stroke, 2017, 48, 1487-1494.	1.0	8
96	Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial. Journal of the American Heart Association, 2017, 6, .	1.6	8
97	Reâ€CHARGEâ€™AF: Recalibration of the CHARGEâ€™AF Model for Atrial Fibrillation Risk Prediction in Patients With Acute Stroke. Journal of the American Heart Association, 2021, 10, e022363.	1.6	8
98	Targeted Minimum Loss-Based Estimation of Causal Effects in Right-Censored Survival Data with Time-Dependent Covariates: Warfarin, Stroke, and Death in Atrial Fibrillation. Journal of Causal Inference, 2013, 1, 235-254.	0.5	7
99	Incremental prognostic value of renal function for stroke prediction in atrial fibrillation. International Journal of Cardiology, 2019, 274, 152-157.	0.8	7
100	A 60-Year-Old Woman With Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2003, 290, 2182.	3.8	6
101	Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administrationâ€™s Approach for Its Product Labeling. Circulation, 2016, 134, 1122-1124.	1.6	6
102	Examining the effects of illicit drug use on tobacco cessation outcomes in the Helping HAND 2 randomized controlled trial. Drug and Alcohol Dependence, 2017, 178, 586-592.	1.6	6
103	Methodologic Differences Across Studies of Patients With Atrial Fibrillation Lead to Varying Estimates of Stroke Risk. Journal of the American Heart Association, 2018, 7, .	1.6	5
104	Comparison of Long-Term Adverse Outcomes in Patients With Atrial Fibrillation Having Ablation Versus Antiarrhythmic Medications. American Journal of Cardiology, 2020, 125, 553-561.	0.7	5
105	Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II). American Journal of Cardiovascular Drugs, 2021, 21, 553-561.	1.0	5
106	Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation. Annals of Internal Medicine, 2000, 132, 841.	2.0	5
107	Comparative Clinical Effectiveness of Populationâ€™Based Atrial Fibrillation Screening Using Contemporary Modalities: A Decisionâ€™Analytic Model. Journal of the American Heart Association, 2021, 10, e020330.	1.6	4
108	Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. American Heart Journal, 2020, 220, 145-154.	1.2	3

#	ARTICLE	IF	CITATIONS
109	Patterns of oral anticoagulation use with cardioversion in clinical practice. <i>Heart</i> , 2021, 107, 642-649.	1.2	3
110	Usefulness of Rhythm Monitoring Following Acute Ischemic Stroke. <i>American Journal of Cardiology</i> , 2021, 147, 44-51.	0.7	3
111	Safety and effectiveness of dabigatran in routine clinical practice: the RE-COVERY DVT/PE study. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 399-409.	1.0	3
112	Management of Adults with Newly Diagnosed Atrial Fibrillation with and without CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 442-453.	3.0	3
113	ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals (GUARD-AF): Rationale and Design of the GUARD-AF Randomized Trial of Screening for Atrial Fibrillation with a 14-day Patch-Based Continuous ECG Monitor. <i>American Heart Journal</i> , 2022, 249, 76-76.	1.2	3
114	Unrecognized History of Transient Atrial Fibrillation at the Time of Discharge from an Index Stroke Hospitalization Is Associated with Increased Recurrent Stroke Risk. <i>Journal of Stroke</i> , 2019, 21, 190-194.	1.4	2
115	Understanding engagement behaviors and rapport building in tobacco cessation telephone counseling: An analysis of audio-recorded counseling calls. <i>Journal of Substance Abuse Treatment</i> , 2021, , 108643.	1.5	2
116	Effect of Temporary Interruption of Warfarin Due to an Intervention on Downstream Time in Therapeutic Range in Patients With Atrial Fibrillation (from ORBIT AF). <i>American Journal of Cardiology</i> , 2020, 132, 66-71.	0.7	1
117	Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in Practice. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008274.	1.4	1
118	Point-of-care screening for atrial fibrillation: Where are we, and where do we go next?. <i>Cardiovascular Digital Health Journal</i> , 2021, 2, 294-297.	0.5	1
119	Warfarin or Not Warfarin?. <i>Annals of Internal Medicine</i> , 2005, 142, 676.	2.0	1
120	Elsewhere correspondence. <i>Hepatology</i> , 1987, 7, 1391-1391.	3.6	0
121	Response to Letter Regarding Article, "Impact of Proteinuria and Glomerular Filtration Rate on Risk of Thromboembolism in Atrial Fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study": <i>Circulation</i> , 2009, 120, .	1.6	0
122	Response to Letter by Willey. <i>Stroke</i> , 2010, 41, .	1.0	0
123	Profile of patients diagnosed with acute venous thromboembolism in routine practice according to age and renal function: RE-COVERY DVT/PE study. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 561-570.	1.0	0
124	Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e022485.	1.6	0
125	Reversal strategies and outcomes in patients with atrial fibrillation and warfarin-associated intracranial hemorrhage. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 104903.	0.7	0